Regado Halts Big Heart Drug Trial, Shares Hammered

Read below for more.

Jul 3, 2014 at 9:02AM

Regado Biosciences (NASDAQ:RGDO) has been trying to show that it doesn't need Big Pharma to run a massive, pricey Phase 3 study on an anticoagulant drug. But the Basking Ridge, NJ-based company suffered a setback Wednesday when it was forced to suspend the trial pending a review of potential safety problems.

Regado said that the data safety monitoring board overseeing the study of its anticoagulant, REG1 (now known as Revolixys Kit), has started an "unplanned review" of the trial. The board will conduct a full analysis of the "safety and treatment benefit-risk ratio" of all the 3,234 patients who have been enrolled in the study so far, focusing on serious adverse events due to allergic reactions to REG1.

Because of the board's move, Regado has stopped enrolling patients in the trial, and will suspend it until the analysis is complete, which should take about eight weeks. Investors immediately pummeled Regado—shares were down more than 38 percent in pre-market trading on Thursday.

This type of news has always been the big risk for Regado, which consciously made a big gamble to run a huge cardiovascular study on its own, believing it could create the most value flying solo. When I spoke with one of Regado's backers last May, a few months before it went public, he mentioned that it would take something "extraordinarily compelling" for the company to partner its lead program. Indeed, Regado rejected potential partnerships on the way into the IPO queue.

Regado's big plan is to try to prove that REG1 is better at preventing strokes and other so-called ischemic events in patients undergoing an angioplasty than The Medicines Co.'s bivalirudin (Angiomax). REG1 is a two-drug system that includes an anticoagulant called pegnivacogin and anivamersen, an RNA aptamer—a string of RNA letters—that binds to pegnivacogin and blocks its activity.

The idea is that by carefully timing injections of each drug a doctor can dial the clot-busting effect up or down in real time during a coronary procedure like an angioplasty. This fine control, Regado says, should make those procedures safer than they otherwise would be. Too much anticoagulation can lead to dangerous bleeding, and none of the other injectable anticoagulants used in such procedures—such as bivalirudin and heparin—have a control agent that can modify their effects.

To test its system, Regado gambled: it chose to run a 13,200-patient study in 500 sites around the world, a job that Big Pharma, and all its financial wherewithal and manpower, is best suited for. That high-risk plan was one of the big reasons Regado had trouble getting out of the IPO gate. Regado has said it expects to pour some $150 million into the trial, and investors were hesitant to buy in during the offering. Regado set a $14 to $16 per share range for its offering, but ultimately priced it at just $4 per share, raising $47 million—all while the IPO window for biotechs was at its peak last August. Regado had to raise more cash subsequently. Now the question is what the data monitoring board will find.

Regado will hold a conference call this morning to discuss the announcement.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

This article originally appeared on Xconomy, along with:

Ben Fidler has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers